ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals logo
$71.47 +1.48 (+2.11%)
Closing price 04:00 PM Eastern
Extended Trading
$71.56 +0.09 (+0.13%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ANIP vs. ADMA, ANVS, MANE, LQDA, and DFTX

Should you buy ANI Pharmaceuticals stock or one of its competitors? ANI Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), Annovis Bio (ANVS), Veradermics (MANE), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ADMA Biologics has a net margin of 35.14% compared to ANI Pharmaceuticals' net margin of 11.22%. ADMA Biologics' return on equity of 42.56% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals11.22% 28.34% 11.18%
ADMA Biologics 35.14%42.56%26.96%

ANI Pharmaceuticals presently has a consensus target price of $100.00, suggesting a potential upside of 42.88%. ADMA Biologics has a consensus target price of $17.50, suggesting a potential upside of 28.39%. Given ANI Pharmaceuticals' higher possible upside, equities analysts plainly believe ANI Pharmaceuticals is more favorable than ADMA Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43
ADMA Biologics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANI Pharmaceuticals$883.37M1.80$78.34M$5.0213.94
ADMA Biologics$510.17M5.93$146.93M$0.7717.70

In the previous week, ADMA Biologics had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 5 mentions for ADMA Biologics and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat ADMA Biologics' score of 0.80 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ADMA Biologics beats ANI Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

ANI Pharmaceuticals has a net margin of 11.22% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 28.34% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -8,315.60% -318.95%
ANI Pharmaceuticals 11.22%28.34%11.18%

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 15.9% of Annovis Bio shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Annovis Bio has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.64N/A
ANI Pharmaceuticals$883.37M1.80$78.34M$5.0213.94

In the previous week, Annovis Bio had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Annovis Bio and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Annovis Bio's score of 0.64 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Annovis Bio currently has a consensus price target of $10.00, suggesting a potential upside of 1,245.90%. ANI Pharmaceuticals has a consensus price target of $100.00, suggesting a potential upside of 42.88%. Given Annovis Bio's higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Veradermics?

Veradermics (NYSE:MANE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Veradermics currently has a consensus target price of $174.57, suggesting a potential upside of 38.81%. ANI Pharmaceuticals has a consensus target price of $100.00, suggesting a potential upside of 42.88%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Veradermics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradermics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Veradermics had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 8 mentions for Veradermics and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Veradermics' score of 0.73 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradermics
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VeradermicsN/AN/A-$70M-$1.90N/A
ANI Pharmaceuticals$883.37M1.80$78.34M$5.0213.94

ANI Pharmaceuticals has a net margin of 11.22% compared to Veradermics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 28.34% beat Veradermics' return on equity.

Company Net Margins Return on Equity Return on Assets
VeradermicsN/A -20.50% -17.66%
ANI Pharmaceuticals 11.22%28.34%11.18%

Summary

ANI Pharmaceuticals beats Veradermics on 10 of the 13 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Liquidia currently has a consensus price target of $75.23, indicating a potential upside of 32.61%. ANI Pharmaceuticals has a consensus price target of $100.00, indicating a potential upside of 42.88%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liquidia
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

ANI Pharmaceuticals has a net margin of 11.22% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Liquidia-15.15% 264.65% 44.19%
ANI Pharmaceuticals 11.22%28.34%11.18%

In the previous week, Liquidia had 28 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 32 mentions for Liquidia and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Liquidia's score of 0.68 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Liquidia
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liquidia$158.32M32.29-$68.92M-$1.23N/A
ANI Pharmaceuticals$883.37M1.80$78.34M$5.0213.94

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Liquidia has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Summary

ANI Pharmaceuticals beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

ANI Pharmaceuticals has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
ANI Pharmaceuticals$883.37M1.80$78.34M$5.0213.94

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 11.22% compared to Definium Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 28.34% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
ANI Pharmaceuticals 11.22%28.34%11.18%

Definium Therapeutics presently has a consensus target price of $66.29, indicating a potential upside of 125.64%. ANI Pharmaceuticals has a consensus target price of $100.00, indicating a potential upside of 42.88%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Definium Therapeutics is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Definium Therapeutics had 9 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 13 mentions for Definium Therapeutics and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Definium Therapeutics' score of 0.60 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ANI Pharmaceuticals beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANIP vs. The Competition

MetricANI PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.59B$13.38B$7.60B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio14.2427.9733.5830.13
Price / Sales1.846.798.275.60
Price / Cash7.0515.6321.0121.90
Price / Book2.555.394.443.72
Net Income$78.34M$2.88B$3.50B$393.88M
7 Day Performance0.53%-5.24%-6.53%-6.07%
1 Month Performance-1.13%-4.80%-4.93%-7.38%
1 Year Performance-11.84%-7.35%-1.73%-7.48%

ANI Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIP
ANI Pharmaceuticals
3.2862 of 5 stars
$71.47
+2.1%
$100.00
+39.9%
-14.6%$1.59B$883.37M14.24970
ADMA
ADMA Biologics
4.041 of 5 stars
$13.46
-1.6%
$17.50
+30.0%
-11.6%$3.03B$519.15M17.48647
ANVS
Annovis Bio
3.6803 of 5 stars
$0.76
-17.8%
$10.00
+1,214.1%
-74.8%$36.45MN/AN/A7
MANE
Veradermics
3.0411 of 5 stars
$127.66
-1.5%
$174.57
+36.8%
N/A$5.71BN/AN/A21
LQDA
Liquidia
3.5459 of 5 stars
$56.37
-1.8%
$75.23
+33.5%
+99.8%$5.24B$158.32MN/A216

Related Companies and Tools


This page (NASDAQ:ANIP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners